11月21日，康拓医疗跌4.72%，成交额3175.10万元。两融数据显示，当日康拓医疗获融资买入额419.67 万元，融资偿还668.98万元，融资净买入-249.32万元。截至11月21日，康拓医疗融资融券余额合计1.04 亿元。 融资方面，康拓医疗当日融资买入419.67万元。当前融资余额1.04亿元，占流通市值的4.17%，融资余 额超过近一年80%分位水平，处于高位。 截至9月30日，康拓医疗股东户数5879.00，较上期增加15.30%；人均流通股13818股，较上期减少 13.27%。2025年1月-9月，康拓医疗实现营业收入2.51亿元，同比增长4.57%；归母净利润7671.52万元， 同比增长0.00%。 分红方面，康拓医疗A股上市后累计派现1.68亿元。近三年，累计派现1.02亿元。 责任编辑：小浪快报 融券方面，康拓医疗11月21日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，西安康拓医疗技术股份有限公司位于陕西省西安市高新区毕原一路西段1451号，成立日期 200 ...

Core Viewpoint - Kangtuo Medical is a leading enterprise in the domestic neurosurgical implant medical device sector, focusing on the research, production, and sales of Class III implantable medical devices, with strong technical barriers [1] Group 1: Business Performance - In Q3 2025, Kangtuo Medical reported revenue of 251 million yuan, ranking 45th out of 50 in the industry, with the industry leader, Yingke Medical, generating 7.425 billion yuan [2] - The net profit for the same period was 75.91 million yuan, placing the company 25th in the industry, while the top performer, Lepu Medical, achieved 999.6 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, Kangtuo Medical's debt-to-asset ratio was 12.72%, down from 13.14% year-on-year, significantly lower than the industry average of 23.66%, indicating strong solvency [3] - The gross profit margin for the same period was 78.69%, slightly down from 80.33% year-on-year, but still well above the industry average of 48.78%, reflecting robust profitability [3] Group 3: Executive Compensation - Chairman Hu Liren's salary for 2024 was 323,800 yuan, an increase of 14,600 yuan from 2023 [4] - General Manager Zhu Hailong's salary for 2024 was 1.4491 million yuan, up by 74,800 yuan from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 15.30% to 5,879, while the average number of circulating A-shares held per account decreased by 13.27% to 13,800 [5]

Core Insights - Kangtuo Medical (688314.SH) reported a revenue of 251 million yuan for the first three quarters of 2025, representing a year-on-year growth of 4.57% [1] - The company's net profit attributable to shareholders remained stable at 76.72 million yuan, showing no change compared to the previous year [1] - The adjusted net profit was 71.61 million yuan, reflecting a year-on-year increase of 7.80% [1] - Basic earnings per share stood at 0.94 yuan [1]

Core Viewpoint - Kangtuo Medical (688314.SH) reported a total operating revenue of 251 million yuan for the first three quarters of 2025, representing a year-on-year increase of 4.57% [1] - The net profit attributable to shareholders of the parent company was 76.71 million yuan, remaining flat compared to the same period last year [1] - The basic earnings per share stood at 0.94 yuan [1] Summary by Category Financial Performance - Total operating revenue for the first three quarters reached 251 million yuan, with a year-on-year growth of 4.57% [1] - Net profit attributable to shareholders was 76.71 million yuan, unchanged from the previous year [1] - Basic earnings per share recorded at 0.94 yuan [1]

Core Viewpoint - Kangtuo Medical (688314.SH) reported a total operating revenue of 251 million yuan for the first three quarters of 2025, representing a year-on-year increase of 4.57% [1] - The net profit attributable to shareholders of the parent company was 76.71 million yuan, remaining flat compared to the same period last year [1] - The basic earnings per share stood at 0.94 yuan [1] Summary by Category Financial Performance - Total operating revenue for the first three quarters reached 251 million yuan, with a year-on-year growth of 4.57% [1] - Net profit attributable to shareholders was 76.71 million yuan, unchanged from the previous year [1] - Basic earnings per share were reported at 0.94 yuan [1]

证券代码：688314 证券简称：康拓医疗 公告编号：2025-039 西安康拓医疗技术股份有限公司 关于调整 2025 年限制性股票激励计划 授予价格的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 二、本次对 2025 年限制性股票激励计划授予价格进行调整的情况 西安康拓医疗技术股份有限公司（以下简称"公司"）于 2025 年 10 月 27 日 召开第二届董事会第十九次会议，审议通过了《关于调整 2025 年限制性股票激 励计划授予价格的议案》，现将有关事项说明如下： 一、公司 2025 年限制性股票激励计划已履行的决策程序和信息披露情况 1、2025 年 4 月 28 日，公司召开第二届董事会第十六次会议，会议审议通 过了《关于公司<2025 年限制性股票激励计划（草案）>及其摘要的议案》《关于 <公司 2025 年限制性股票激励计划实施考核管理办法>的议案》《关于提请股东 会授权董事会办理公司 2025 年限制性股票激励计划相关事宜的议案》。 同日，公司召开第二届监事会第十二次会议，审议通过了《关于公司<20 ...

国浩律师（西安）事务所 关 于 西安康拓医疗技术股份有限公司 2025 年限制性股票激励计划调整相关事项 之 | | | 法 律 意 见 书 西安市雁塔区绿地中心 B 座 46 层 邮编：710065 The 46th Floor, Block B, Xi'an Greenland Center, Yanta District, Xi'an，710065,China 电话/Tel: +86 29 8819 9711 网址/Website: http://www.grandall.com.cn 2025 年 10 月 国浩律师(西安)事务所 法律意见书 国浩律师（西安）事务所 关于西安康拓医疗技术股份有限公司 2025 年限制性股票激励计划调整相关事项之 法律意见书 致：西安康拓医疗技术股份有限公司 国浩律师（西安）事务所（以下简称"本所"）接受西安康拓医疗技术股 份有限公司委托，担任其 2025 年限制性股票激励计划的特聘专项法律顾问。 本所律师根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股权激励管理办法》《上海证券交易所科创板股票上市规则》《科创板 上市公司信息披露业务指南第 4 号—— ...

Group 1 - The core viewpoint of the article highlights the financial performance of Kangtuo Medical in Q3 2025, showing a revenue increase and a positive net profit [1] - Kangtuo Medical reported a revenue of approximately 251 million yuan for the first three quarters of 2025, representing a year-on-year increase of 4.57% [1] - The net profit attributable to shareholders of the listed company was approximately 76.72 million yuan [1] Group 2 - As of the report date, Kangtuo Medical has a market capitalization of 2.9 billion yuan [2]

证券代码：688314 证券简称：康拓医疗 公告编号：2025-040 西安康拓医疗技术股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 11 月 04 日（星期二）14:00-15:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 10 月 28 日（星期二）至 11 月 03 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 public@kontmed.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 西安康拓医疗技术股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥80,772,405.35, a decrease of 6.92% compared to the same period last year[4] - The total profit for the period was ¥24,365,076.68, reflecting a decline of 26.31% year-on-year[4] - The net profit attributable to shareholders was ¥21,716,516.65, down 22.22% from the previous year[4] - Total operating revenue for the first three quarters of 2025 reached ¥251,088,755.11, an increase of 4.1% compared to ¥240,117,907.83 in the same period of 2024[19] - Total operating costs for the first three quarters of 2025 were ¥156,565,067.29, up from ¥148,313,124.73 in 2024, reflecting a year-over-year increase of 5.5%[19] - Net profit for the first three quarters of 2025 was ¥75,906,135.43, slightly down from ¥76,006,339.62 in 2024, indicating a decrease of 0.1%[20] - The company reported a total profit of ¥89,724,401.40 for the first three quarters of 2025, compared to ¥92,332,439.71 in 2024, reflecting a decrease of 2.8%[20] Research and Development - Research and development expenses totaled ¥10,114,843.75, an increase of 23.61% compared to the same quarter last year, representing 12.52% of operating revenue[5] - Research and development expenses for the first three quarters of 2025 were ¥17,980,206.24, up from ¥16,399,769.03 in 2024, representing an increase of 9.7%[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥790,933,245.95, an increase of 5.85% from the end of the previous year[5] - The equity attributable to shareholders increased by 8.29% year-on-year, reaching ¥688,268,864.98[5] - The company's total liabilities decreased to ¥100,587,268.91 in 2025 from ¥109,374,780.75 in 2024, a reduction of approximately 8.1%[17] - The total equity attributable to shareholders increased to ¥688,268,864.98 in 2025, compared to ¥635,577,490.21 in 2024, marking an increase of about 8.3%[17] Cash Flow - The net cash flow from operating activities was ¥23,893,689.92, down 29.17% year-on-year[5] - The company’s cash flow from operating activities for the first three quarters of 2025 showed a positive trend, although specific figures were not disclosed in the provided data[21] - In the first three quarters of 2025, the cash inflow from operating activities was CNY 287,099,764.83, a slight decrease of 0.65% compared to CNY 288,963,805.42 in the same period of 2024[22] - The net cash flow from operating activities decreased to CNY 86,083,545.57, down 21.5% from CNY 109,654,732.43 year-on-year[22] - Cash inflow from investment activities totaled CNY 629,164,479.21, significantly increasing by 81.1% from CNY 347,020,186.10 in the previous year[23] - The net cash flow from investment activities was negative at CNY -193,046,531.01, worsening from CNY -151,796,237.78 in the same period last year[23] - Cash outflow from financing activities was CNY 33,577,694.13, compared to CNY 29,942,653.10 in the previous year, reflecting an increase of 8.7%[23] - The ending balance of cash and cash equivalents decreased to CNY 237,174,086.51, down 21.6% from CNY 302,407,498.71 at the end of the same period last year[23] Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 5,879[11] - The largest shareholder, Hu Liren, holds 39,545,788 shares, representing 48.68% of total shares[11] Current Assets - Total current assets as of September 30, 2025, amount to ¥422,128,968.67, slightly up from ¥418,250,595.94 at the end of 2024[15] - Cash and cash equivalents decreased to ¥237,963,156.13 from ¥378,532,413.99[15] - Accounts receivable increased to ¥8,893,422.12 from ¥5,916,765.08, indicating a growth of 50.5%[15] - Inventory increased to ¥30,934,238.91 from ¥24,750,588.76, reflecting a rise of 24.9%[15] - Non-current assets total ¥368,804,277.28, up from ¥328,972,266.97[16] - Total assets increased to ¥790,933,245.95 from ¥747,222,862.91[16] - Current liabilities include accounts payable of ¥26,140,856.99, slightly up from ¥25,845,698.39[16] - The company has no short-term borrowings reported as of September 30, 2025[16] Other Information - The company reported a total of ¥195,239.57 in government subsidies recognized during the period, contributing positively to the financial results[7] - The company has not disclosed any significant new product developments or market expansion strategies in this report[10] - The company has not reported any net profit from mergers under common control for the current or previous periods, indicating no impact from such activities on the financial results[21] - The company experienced a negative impact of CNY -28,578.29 from exchange rate fluctuations on cash and cash equivalents[23]